The FDA also advises against using unapproved or compounded versions of semaglutide, as they may not meet safety standards
Frontiers in Endocrinology, 14, 1215356
Available at: 132 WitkowskiMWilkinsonLWebbNWeidsAGlahDVrazicH
This review documents enrollment steps, pricing presentation, medication access descriptions, clinician authority, and platform limits as shown across Ivim Healths public pages
The absolute risk appears relatively small
The purported health benefits now appear to be even more far-reaching, with the latest data from a trial called Select, published in 2023, showing that semaglutide can slash the risk of heart attacks and strokes by a fifth in patients with an existing history of cardiovascular disease